ArticleAdvances in therapy2026

Safety, Efficacy, and Pharmacokinetics of Agalsidase Alfa in Treatment-Naive Chinese Patients with Fabry Disease: 52-Week Phase 3, Open-Label, Single-Arm Study.

Hong Ren et al.PubMed ↗Publisher ↗

No numbers read from the abstract.